Pictilisib (GDC-0941)

For research use only. Not for use in humans.

目录号：S1065 别名： RG7321

Pictilisib (GDC-0941) Chemical Structure

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) 是一种有效的PI3Kα/δ抑制剂，在无细胞试验中IC50为 3 nM，对p110β (11倍)和p110γ (25倍)具有适度的选择性。Pictilisib (GDC-0941) 可诱导自噬和凋亡。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1972.48	现货
5mg	RMB 986.88	现货
10mg	RMB 1390.74	现货
50mg	RMB 3026.17	现货
200mg	RMB 7926.11	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Pictilisib (GDC-0941)发表文献307篇：

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2017, 23(11):1342-1351

PubMed: 29035366 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cell, 2013, 7;155(4):844-57.

PubMed: 24209622 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(3):289-296

PubMed: 32094692 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2291

PubMed: 32385243 ( click the link to review the publication )

Nat Commun, 2020, 11(1):1290

PubMed: 32157087 ( click the link to review the publication )

EMBO Mol Med, 2020, e11674

PubMed: 32558386 ( click the link to review the publication )

Cell Syst, 2020, 20;10(5):384-396.e9

PubMed: 32437683 ( click the link to review the publication )

Cell Syst, 2020, 10(3):240-253

PubMed: 32191874 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 30(13):4584-4599

PubMed: 32234489 ( click the link to review the publication )

J Control Release, 2020, 318:98-108

PubMed: 31838203 ( click the link to review the publication )
Sci Signal, 2020, 13(637):eaba8627

PubMed: 32576681 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

Front Oncol, 2020, 1;10:393

PubMed: 32296637 ( click the link to review the publication )

Sci Rep, 2020, 4;10(1):7401

PubMed: 32366879 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Eur J Pharmacol, 2020, 873:172981

PubMed: 32014486 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):533-540

PubMed: 32565979 ( click the link to review the publication )

J Cell Biol, 2020, 219(2)

PubMed: 31914171 ( click the link to review the publication )

Oncotarget, 2020, 28;11(17):1493-1504

PubMed: 32391119 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

J Clin Invest, 2019, 129(12):5584-5599

PubMed: 31527310 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(9):2835-2847

PubMed: 30670492 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2892-2908

PubMed: 31048499 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )
Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

MBio, 2019, 10(1)

PubMed: 30755508 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Invest Dermatol, 2019, 139(9):2004-2015

PubMed: 31059696 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(12):2395-2409

PubMed: 31548239 ( click the link to review the publication )

J Transl Med, 2019, 17(1):431

PubMed: 31888636 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):431-442

PubMed: 30483742 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Pestic Biochem Physiol, 2019, 154:67-77

PubMed: 30765058 ( click the link to review the publication )

Contrast Media Mol Imaging, 2019, 2019:1760184

PubMed: 31787861 ( click the link to review the publication )

Life Sci Alliance, 2019, 2(6)

PubMed: 31704709 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )
Mol Cell, 2018, 71(6):1092-1104

PubMed: 30174291 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4945

PubMed: 30470748 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30545064 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):71

PubMed: 30237393 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(6)

PubMed: 29514810 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2018, 315(6):L965-L976

PubMed: 30211651 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2018, 58(2):181-193

PubMed: 28915060 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

Invest New Drugs, 2018, 36(5):763-772

PubMed: 29504069 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Prostate, 2018, 78(13):1013-1023

PubMed: 30133757 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):715-725

PubMed: 29901201 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

PLoS One, 2018, 13(8):e0200725

PubMed: 30067771 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

JCI Insight, 2018, 3(4)

PubMed: 29467326 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2249

PubMed: 29269732 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(16):9654-9678

PubMed: 28934469 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )
Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Oncogene, 2017, 36(41):5681-5694

PubMed: 28604746 ( click the link to review the publication )

Oncogene, 2017, 36(36):5110-5121

PubMed: 28481878 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2130-2143

PubMed: 28751539 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Cell Discov, 2017, 3:16054

PubMed: 28224045 ( click the link to review the publication )

Mol Pharm, 2017, 14(7):2368-2377

PubMed: 28597653 ( click the link to review the publication )

J Immunol, 2017, 198(2):657-668

PubMed: 27940659 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7(1):3964

PubMed: 28638122 ( click the link to review the publication )

Mol Pharmacol, 2017, 91(1):65-73

PubMed: 27821547 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(10):816-826

PubMed: 29099264 ( click the link to review the publication )

Biol Reprod, 2017, 97(5):671-687

PubMed: 29036279 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181243

PubMed: 28704514 ( click the link to review the publication )

Curr Cancer Drug Targets, 2017, 17(8):722-734

PubMed: 28359246 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncotarget, 2017, 8(3):5349-5360

PubMed: 28029662 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )
Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(2):3259-3273

PubMed: 27965462 ( click the link to review the publication )

Oncotarget, 2017, 8(26):42343-42358

PubMed: 28418845 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

Oncotarget, 2017, 8(8):12558-12575

PubMed: 28147342 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Physiol Rep, 2017, 5(18)

PubMed: 28947594 ( click the link to review the publication )

Oncotarget, 2017, 8(47):83052-83062

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 9(10):8870-8886

PubMed: 29507660 ( click the link to review the publication )

Nat Commun, 2016, 7:13567

PubMed: 27876799 ( click the link to review the publication )

Nat Commun, 2016, 7:13650

PubMed: 27897192 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cell Rep, 2016, 15(12):2692-704

PubMed: 27292631 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27700986 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Oncogene, 2016, 35(27):3587-97

PubMed: 26549034 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(3):317-28

PubMed: 26850518 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1545-56

PubMed: 27196766 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(6):1248-60

PubMed: 27197306 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):94-105

PubMed: 26637365 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(12):3507-3519

PubMed: 27992857 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:37213

PubMed: 27849011 ( click the link to review the publication )

PLoS Comput Biol, 2016, 12(4):e1004827

PubMed: 27035903 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )

Oncotarget, 2016, 7(28):44448-44461

PubMed: 27286446 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43124-43149

PubMed: 27281609 ( click the link to review the publication )

Oncotarget, 2016, 7(36):57525-57544

PubMed: 27438153 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82424-82439

PubMed: 27489350 ( click the link to review the publication )

Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Nat Commun, 2015, 6:7935

PubMed: 26228240 ( click the link to review the publication )

Nat Commun, 2015, 6:8501

PubMed: 26442967 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Elife, 2015, 4:e10510

PubMed: 26523394 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(12):3115-3124

PubMed: 26302068 ( click the link to review the publication )
Sci Signal, 2015, 8(401):ra111

PubMed: 26535009 ( click the link to review the publication )

Sci Signal, 2015, 8(396):ra96

PubMed: 26420907 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

J Biol Chem, 2015, 290(35):21705-12

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Proteomics, 2015, 15(2-3):327-39

PubMed: 25339196 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(3):402-11

PubMed: 25692408 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0143357

PubMed: 26580203 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0122689

PubMed: 25837824 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0131400

PubMed: 26148118 ( click the link to review the publication )

Oncotarget, 2015, 6(11):9189-205

PubMed: 25826077 ( click the link to review the publication )

Oncotarget, 2015, 6(39):41976-87

PubMed: 26506516 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )
Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015, 96(3):507-17

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

Oncotarget, 2015, 6(31):32089-103

PubMed: 26392332 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(18):16488-506

PubMed: 26029997 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33091-105

PubMed: 26384305 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(47):16826-9

PubMed: 25385636 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(26):3422-31

PubMed: 23912457 ( click the link to review the publication )

Oncogene, 2014, 33(8):966-76

PubMed: 23474757 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )
Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Am J Cancer Res, 2014, 4(6):824-37

PubMed: 25520871 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Mol Med Rep, 2014, 9(1):83-90

PubMed: 24213221 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7081-92

PubMed: 25216524 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7328-41

PubMed: 25193862 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7936-44

PubMed: 25277205 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(15):6512-25

PubMed: 25156567 ( click the link to review the publication )

Oncotarget, 2014, 5(13):5040-53

PubMed: 24970815 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Sci Transl Med, 2013, 5(196):196ra98

PubMed: 23903755 ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )
Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cancer Res, 2013, 73(3):1190-200

PubMed: 23204226 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Haematologica, 2013, 98(1):57-64

PubMed: 22801959 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

Sci Signal, 2013, 6(288):ra68

PubMed: 23943608 ( click the link to review the publication )

Sci Signal, 2013, 6(268):ra20

PubMed: 23532334 ( click the link to review the publication )

PLoS Genet, 2013, 9(2):e1003253

PubMed: 23459592 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2950-61

PubMed: 24107445 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Front Genet, 2013, 4:34

PubMed: 23543623 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):557-61

PubMed: 23665330 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(8):1185-98

PubMed: 23852390 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )
Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Oncotarget, 2012, 3(8):811-23

PubMed: 22885370 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Thyroid, 2010, 20(7):689-95

PubMed: 20578898 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

体外研究

GDC-0941也等效作用于PI3Kα和 PI3Kδ和PI3Kα突变型E545-K和H1047-R,也选择性作用于PI3Kβ(10倍)和 PI3Kγ(25倍), 选择性更高地作用于PI3K II, III, 和IV类成员，包括, C2β, Vps34, DNA-PK和mTOR。GDC-0941 作用于U87MG, PC3, 和 MDA-MB-361 细胞，有效抑制Akt磷酸化，IC50分别为46 nM, 37 nM,和 28 nM。GDC-0941抑制U87MG, A2780, PC3, 和MDA-MB-361细胞增殖，IC50分别为 0.95 μM, 0.14 μM, 0.28 μM, 和0.72 μM。^[1]GDC-0941处理，有效抑制对Trastuzumab敏感和不敏感的HER2扩增细胞增殖，IC50为149-944 nM,与 Trastuzumab敏感性无关。GDC-0941抑制含PIK3CA突变的HER2扩增的细胞增殖，IC50<500 nM, 且有效抑制抗trastuzumab 的HER2 扩增乳腺癌细胞增殖和活力。^[2]GDC-0941 显著抑制HCT116, DLD1和 HT29细胞生长，GI50分别为1081 nM, 1070 nM 和157 nM。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	NYXBO2hVU2mwYYPlJGF{e2G7		MWixJIg>	NYLJUFFMTE2VTx?=	MljmTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh\|ryP	M1THWVE5PzV2NkW0
Sf9	NYjY[pRUU2mwYYPlJGF{e2G7		NUjiU4FWOSCq	NUTN[FhPTE2VTx?=	NGH4dZBKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEhUDFyNEetVkBufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	MU[xPFc2PDZ3NB?=
Sf9	MoLrT4lv[XOnIFHzd4F6		NXnKd5lSOSCq	NF;NPZFFVVOR	M{LiWWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYnX0ZUBGPTR3LVugcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>	M4LTeVE5PzV2NkW0
Sf9	NYL0[pBtU2mwYYPlJGF{e2G7		MnfLNUBp	NGTjdYxFVVOR	NGXDXopKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIEhf2m2aDDJR\|UxKG:oIECuNFM{KM7:TR?=	MlnkNVg4PTR4NUS=
Sf9	M1jCWmtqdmG\|ZTDBd5NigQ>?		MlLqNUBp	NVjYfFFGTE2VTx?=	M2X3TmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiUFmzT{BxOTFyYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIE>	NFXTVHIyQDd3NE[1OC=>
MDA-MB-361	MmrZSpVv[3Srb36gRZN{[Xl?		MkHKNkBp	Mn3wSG1UVw>?	MYrJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlAzQCEQvF2=	NGKyblAyQDd3NE[1OC=>
PC3	MonnSpVv[3Srb36gRZN{[Xl?		NHrW[m4zKGh?	MVPEUXNQ	MofmTY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdiCrbjDQWGVPNW63bHygbJVu[W5iUFOzJINmdGy\|IIfpeIghUUN3MDDv[kAxNjB\|NzFOwG0>	NVTLOosxOTh5NUS2OVQ>
U87MG	M4fIeGZ2dmO2aX;uJGF{e2G7		M3\ad\|IhcA>?	M1rWZ2ROW09?	NULrNXhvUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBRXEWQLX71cIwhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDJR\|UxKG:oIECuNFQ3KM7:TR?=	NITZVGYyQDd3NE[1OC=>
MDA-MB-361	MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{Puelk3KGh?	MWHEUXNQ	NXHtWZYzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC55MjFOwG0>	NUO2NYRIOTh5NUS2OVQ>
A2780	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3rZO\|k3KGh?	M4fZdGROW09?	NYfEdpoxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	NVjDN3k1OTh5NUS2OVQ>
PC3	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoXmPVYhcA>?	M4LnU2ROW09?	MUjJR\|UxRTBwMkig{txO	NUDyT2h5OTh5NUS2OVQ>
U87MG	NV\uZlZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEf3VW06PiCq	MU\EUXNQ	MmT6TWM2OD1yLkm1JO69VQ>?	NITJd2YyQDd3NE[1OC=>
Sf9	MofBT4lv[XOnIFHzd4F6		NVqycpNMOzBibXnu	MmPtSG1UVw>?	M1TJSWlvcGmkaYTpc44hd2ZiaIXtZY4hWEl\|S3fhcY1iKGW6cILld5Nm\CCjc4Pld5Nm\CCjczDhcY92dnRib3[gRXRRKGOxboP1cYVlKHerdHigTWM2OCCxZjCwMlA1OiEQvF2=	NH\aSWEzOjV2OEO0Ni=>
RAW 264.7	NYS2SYlxU2mwYYPlJGF{e2G7		MnLhPVAhdWmw	NYPROoVNTE2VTx?=	NXrVXGVOUW6qaXLpeIlwdiCxZjDoeY1idiCSSUPL[4FudWFiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5{OUig{txO	MnvuNlI2PDh\|NEK=
Sf9	MV3LbY5ie2ViQYPzZZk>		NUO3V5NXOSCq		MmjPTY5pcWKrdHnvckBw\iCJU2St[pV{\WRiaIXtZY4hemWlb33ibY5idnRiUFmzT4JmfGFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOIOTDj[YxteyC5aYToJGlEPTBib3[gNE4xOTdizszN	NEeyXXozOzV2ME[0OS=>
Sf9	MnfyT4lv[XOnIFHzd4F6		NVHXXXV5OSCq		MVrJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPL[IVtfGFiZYjwdoV{e2Wm	NEfJTpczOzV2ME[0OS=>
Sf9	NHfmVmVMcW6jc3WgRZN{[Xl?		MX:xJIg>		M3WzTGlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2to[W2vYTDlfJBz\XO\|ZXS=	MonNNlM2PDB4NEW=
Sf9	NGTwZ4VMcW6jc3WgRZN{[Xl?		MmLFNUBp		MXfJcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPLZYxxcGFiZYjwdoV{e2Wm	MXSyN\|U1ODZ2NR?=
SKOV3	MVLLbY5ie2ViQYPzZZk>	M4DBUVEh\|ryP	M2LB[VEhcA>?	MmDnSG1UVw>?	MnzxTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDa4SgV4VzPDd\|IIDoc5NxcG:{eXzheIlwdg>?	M4DrWlI{OzZyM{S4
MCF7	M4r6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlGxNUDPxE1?	NEnWOHI6PiCq	NVmyXGJjTE2VTx?=	NGqz[pBIUTVyPUCuNFcxOiEQvF2=	NVu2[21iOjN\|NkCzOFg>
SKOV3	NVzxcJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPBPW8yKM7:TR?=	M3\zU\|k3KGh?	MYfEUXNQ	MYjHTVUxRTBwMUS3OkDPxE1?	M1XwTlI{OzZyM{S4
PC3	NWm4PWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFPvWYk4OiCq	NXrFO2h5TE2VTx?=	MnTKTWM2OD1yLkK4JO69VQ>?	M4jOXFIyQThzN{G0
MCF7.1	NUH2Oo1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mmf3O\|IhcA>?	MlLqSG1UVw>?	NHfuXYFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKEiHUkKg[4Vv\SC5aYToJGlEPTBib3[gNE4zQCEQvF2=	M3TYOVIyQThzN{G0
MCF7-neo/Her2	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIrEO204OiCq	NEPYfGJFVVOR	MoTYTWM2OD1yLkK5JO69VQ>?	M4TzWlI{PjZ{OUCz
MCF7-neo/Her2	NX;lR4xMU2mwYYPlJGF{e2G7				M{DWZ2lvcGmkaYTpc44hd2ZiUFmzT4FteGijIHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIHH0JHM1PzNid3n0bEBKSzVyIH;mJFAvODB5IN88US=>	M4TQcFI{PjZ{OUCz
PC3	M{TSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXvZeGhsPzJiaB?=	MWnEUXNQ	M{fNcGVEPTB;MD6zOEDPxE1?	M4TMXlIyQTh3NkO5
MCF7.1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NU\idWVUPzJiaB?=	M2DSRmROW09?	MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCHQ{WwJI9nKDBwM{mg{txO	Mk\UNlE6QDV4M{m=
PC3	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVy3NkBp	NG\h[nVFVVOR	NYXFcox3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOg[IVncWOrZX70JIlvKFCWRV6ge4l1cCCLQ{WwJI9nKDBwM{mg{txO	NIW2ZVYzODB3ME[2PS=>
MCF7.1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYi1W3luPzJiaB?=	MUnEUXNQ	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCLQ{WwJI9nKDBwM{Sg{txO	NFnJe5kzODB3ME[2PS=>
MCF7.1	Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XR[lczKGh?		NF\CSpJGSzVyPUCuO\|Ih\|ryP	NV33dVJ2OjB\|NE[2OVY>
NCI-H1975	MYTDfZRwfG:6aXOgRZN{[Xl?		NEK0e5I4OiCq		NUHwdoJNUUN3ME2wMlI4KM7:TR?=	M1nYcFI{ODV7NUS1
H460	NX6zN3RoS3m2b4TvfIlkKEG\|c3H5		MVi3NkBp		NFTY[XVKSzVyPUCuPFch\|ryP	MV:yN\|A2QTV2NR?=
HT-29	M3vOd2N6fG:2b4jpZ{BCe3OjeR?=		MXu3NkBp		NF;pO5FKSzVyPUCuOlYh\|ryP	NVXxW3A2OjNyNUm1OFU>
HepG2	Mnv2R5l1d3SxeHnjJGF{e2G7		NFn5bXE4OiCq		MkLSTWM2OD1zIN88US=>	MYKyN\|A2QTV2NR?=
SGC7901	NXnqWplNS3m2b4TvfIlkKEG\|c3H5		M3\HV\|czKGh?		M3u2W2lEPTB;MT64JO69VQ>?	M1\NcFI{ODV7NUS1
NCI-H226	MWnDfZRwfG:6aXOgRZN{[Xl?		MmHWO\|IhcA>?		M2q4cmlEPTB;Mj65JO69VQ>?	NIm0bo0zOzB3OUW0OS=>
A549	MkWxR5l1d3SxeHnjJGF{e2G7		M1XkNVczKGh?		Mkj4TWM2OD14Lkmg{txO	MkLlNlMxPTl3NEW=
U87MG	MXXDfZRwfG:6aXOgRZN{[Xl?		NYfXU2dpPzJiaB?=		M{frVGlEPTB;Nz63O{DPxE1?	NH3VcYYzOzB3OUW0OS=>
HBC4	NFPB[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLTTVZtd2eJSUWwQU03NjB\|IF2=	MlrMNlI{OzZ{NE[=
BSY1	M4qyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDpOWo2dG:pR1m1NF0uPi57MDDN	M{XBRVIzOzN4MkS2
HBC5	NGL1NFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzUbpJxdG:pR1m1NF0uPi54MDDN	M3XPbVIzOzN4MkS2
MCF7	NVqwcZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTQXGttd2eJSUWwQU04NjN\|IF2=	NUfrfFJ1OjJ\|M{[yOFY>
MDA-MB-231	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPpcI9oT0l3ME2tOU41PiCP	NW\NOXdLOjJ\|M{[yOFY>
U251	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTXVnhldG:pR1m1NF0uPS53MDDN	MUKyNlM{PjJ2Nh?=
SF268	NVTWdHVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\UcI9oT0l3ME2tOU4{QSCP	MUeyNlM{PjJ2Nh?=
SF295	NV;aN\|A{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{e3Ooxw\0eLNUC9MVYvOzdiTR?=	M175XlIzOzN4MkS2
SF539	M2K1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDkT\|FPdG:pR1m1NF0uPi53MDDN	MorhNlI{OzZ{NE[=
SNB75	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTFcI9oT0l3ME2tO{4yOCCP	MmnENlI{OzZ{NE[=
SNB78	MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHsc4dIUTVyPT22MlUzKE1?	Mo\zNlI{OzZ{NE[=
HCC2998	M1Hx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLscI9oT0l3ME2tOk4zQSCP	NILQdnIzOjN\|NkK0Oi=>
KM12	NEHBNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\WNoxw\0eLNUC9MVUvPzZiTR?=	MlXaNlI{OzZ{NE[=
HT-29	NUHnWGZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrsc4dIUTVyPT22MlMxKE1?	NXfkSG1{OjJ\|M{[yOFY>
HCT15	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nNdYxw\0eLNUC9MVYvOTJiTR?=	MVeyNlM{PjJ2Nh?=
HCT116	M{WzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfJcI9oT0l3ME2tOU45PyCP	M4n0S\|IzOzN4MkS2
NCI-H23	M{njSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLzcI9oT0l3ME2tOU44OyCP	M2TXSVIzOzN4MkS2
NCI-H226	NFznTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\sc4dIUTVyPT22MlIyKE1?	M4TVblIzOzN4MkS2
NCI-H522	M3Ln[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXVcI9oT0l3ME2tOk42QCCP	NYnQVXJYOjJ\|M{[yOFY>
NCI-H483	NHXLRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjsc4dIUTVyPT22MlU3KE1?	MX[yNlM{PjJ2Nh?=
A549	NVjFcHJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDtVllydG:pR1m1NF0uPi5zNTDN	NX;4fIN3OjJ\|M{[yOFY>
DMS273	NHnsd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnsc4dIUTVyPT22MlQ{KE1?	MX:yNlM{PjJ2Nh?=
DMS114	M2fCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDTd4ZRdG:pR1m1NF0uPS57MjDN	MXeyNlM{PjJ2Nh?=
LOXIMVI	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHSSGNtd2eJSUWwQU03NjJ7IF2=	MnrHNlI{OzZ{NE[=
OVCAR3	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\sc4dIUTVyPT22MlcyKE1?	M133dlIzOzN4MkS2
OVCAR4	MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELVcW1td2eJSUWwQU02Njd4IF2=	NWXmNnBLOjJ\|M{[yOFY>
OVCAR5	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{O2W4xw\0eLNUC9MVYvOjZiTR?=	NU\Cc3pKOjJ\|M{[yOFY>
OVCAR8	NFXScohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYPCbnN6dG:pR1m1NF0uPS55MzDN	MXWyNlM{PjJ2Nh?=
SKOV3	NGrqSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HWZ4xw\0eLNUC9MVYvPTJiTR?=	MXSyNlM{PjJ2Nh?=
RXF631L	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{L1fIxw\0eLNUC9MVYvQDhiTR?=	M4\k[VIzOzN4MkS2
ACHN	NXnaOolUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;yNm1VdG:pR1m1NF0uPi5yNzDN	M{P2flIzOzN4MkS2
St-4	NXG0c29rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPsc4dIUTVyPT21MlU3KE1?	M1TZWFIzOzN4MkS2
MKN1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPGUGpHdG:pR1m1NF0uPy5yODDN	NYrITocxOjJ\|M{[yOFY>
MKN7	M{HITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLscI9oT0l3ME2tOk42OCCP	Ml3CNlI{OzZ{NE[=
MKN28	NITqNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF6y[\|htd2eJSUWwQU02NjV{IF2=	NVvtRVVyOjJ\|M{[yOFY>
MKN45	NWf4bYF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml36cI9oT0l3ME2tOk42PSCP	M{\rfFIzOzN4MkS2
MKN74	NGnOR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DQRYxw\0eLNUC9MVYvODJiTR?=	MV:yNlM{PjJ2Nh?=
DU145	NETsOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEToR\|Vtd2eJSUWwQU02Njh3IF2=	MU[yNlM{PjJ2Nh?=
PC3	NULqSGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7sc4dIUTVyPT22MlY3KE1?	MW[yNlM{PjJ2Nh?=
ES5	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTVyLkKxJI5O	MYXTRW5ITVJ?
HH	Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfBTWM2OD1zMUGuNFghdk1?	M4[4WXNCVkeHUh?=
MHH-PREB-1	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M12ze2lEPTB;MUG0MlMhdk1?	NX:zU2x7W0GQR1XS
NCI-H1770	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LKc2lEPTB;MUKzMlg3KG6P	M1znXXNCVkeHUh?=
HuO9	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\CTWM2OD1{ME[uNFIhdk1?	MXTTRW5ITVJ?
HAL-01	M1zibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fydWlEPTB;MkC2Mlc{KG6P	MofXV2FPT0WU
NOS-1	NYWyU3pET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLkTWM2OD1{MUGuPFIhdk1?	NUmyRXB[W0GQR1XS
HGC-27	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTRV4ZKSzVyPUKxNk42PyCwTR?=	MlHKV2FPT0WU
NB69	NEL4TGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3yzTmlEPTB;MkS1MlI4KG6P	MnL6V2FPT0WU
RS4-11	NHvITplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDLN3hKSzVyPUK2NU44PiCwTR?=	M133[HNCVkeHUh?=
DOK	NGWxfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\Je5Z1UUN3ME2zNFEvPyCwTR?=	NV3SSWhEW0GQR1XS
LB2241-RCC	M1TnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTNyMz64OEBvVQ>?	M{XXXnNCVkeHUh?=
NCI-H1623	NEPnN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLaRZpKSzVyPUOwOE4xQCCwTR?=	MVnTRW5ITVJ?
YH-13	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTNyND6zNkBvVQ>?	M1P4VnNCVkeHUh?=
BPH-1	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3rTWM2OD1\|MUSgcm0>	NIDUVlFUSU6JRWK=
AN3-CA	M4[zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn72TWM2OD1\|NECuN\|chdk1?	NHvHemZUSU6JRWK=
ES7	NXjHO\|JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XMZ2lEPTB;M{SxMlk6KG6P	MWnTRW5ITVJ?
MDA-MB-175-VII	NXLyfWp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTN3Mj65NkBvVQ>?	NYDZenJyW0GQR1XS
GAMG	NF3Od41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLzRoJ7UUN3ME2zO\|AvQDVibl2=	NXXJZ4J4W0GQR1XS
CHL-1	NHi1[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFy1VGJKSzVyPUO3PE43PSCwTR?=	MWPTRW5ITVJ?
NB7	M{PWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTN6OT64N{BvVQ>?	NYrUOVdKW0GQR1XS
MFE-280	NEfabXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XzVGlEPTB;NEG4MlIhdk1?	M1H2S3NCVkeHUh?=
HL-60	M4XteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTR{NT63OUBvVQ>?	NGDtcXVUSU6JRWK=
GCIY	M2q2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjL[4xYUUN3ME20N\|MvQCCwTR?=	MYXTRW5ITVJ?
MDA-MB-361	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLKVHN5UUN3ME20N\|kvOTNibl2=	MWPTRW5ITVJ?
LXF-289	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LNeWlEPTB;NES4MlI4KG6P	NX[zRXo6W0GQR1XS
NBsusSR	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTR6OD64OUBvVQ>?	M1;2S3NCVkeHUh?=
KU-19-19	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnObHFxUUN3ME21NVYvODdibl2=	M{HIR3NCVkeHUh?=
A204	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjYTWM2OD13MkKuN\|Mhdk1?	M3q5dHNCVkeHUh?=
LB1047-RCC	M3ftUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnDNY5KSzVyPUWyNk46OyCwTR?=	MmDlV2FPT0WU
COLO-684	NV3N[WRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LmUGlEPTB;NUKzMlEyKG6P	NEnNZWxUSU6JRWK=
PA-1	M2Hjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVu5VZZFUUN3ME21N\|IvPDFibl2=	NFzNbo5USU6JRWK=
MG-63	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTV2MT6xNUBvVQ>?	NHLGbXJUSU6JRWK=
BHT-101	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV25NVM2UUN3ME21OFQvQTRibl2=	MmfvV2FPT0WU
NKM-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rOdGlEPTB;NUmzMlA6KG6P	NXrqSmtyW0GQR1XS
T47D	M{jWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zhdmlEPTB;NUm3MlU3KG6P	NV;JO2VRW0GQR1XS
MOLT-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPiTFE{UUN3ME22NlMvPjJibl2=	NFi2dllUSU6JRWK=
IGROV-1	MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3oWo1GUUN3ME22N\|QvOzFibl2=	M4r5XnNCVkeHUh?=
ES4	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzxTWM2OD14M{muOVQhdk1?	M2[2dHNCVkeHUh?=
HuO-3N1	M1TmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mni5TWM2OD14NEKuN\|ghdk1?	MmnUV2FPT0WU
NEC8	MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTZ3Mz61O{BvVQ>?	NVPQNoJ{W0GQR1XS
HO-1-N-1	NYPKRol5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX72dFd[UUN3ME22OVkvOTdibl2=	MVrTRW5ITVJ?
EPCL-272H	NIDhS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTZ6Nz6yNUBvVQ>?	NG\ENmtUSU6JRWK=
D-263MG	M3TXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf2XXhKSzVyPUexPE4yKG6P	M3vzXHNCVkeHUh?=
MV-4-11	NEPyfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\WXWlEPTB;N{K0MlMyKG6P	NY[4cVk1W0GQR1XS
SK-NEP-1	M4PIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDnRVRKSzVyPUeyOU46PCCwTR?=	M3P3fnNCVkeHUh?=
SW872	MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NED3OlJKSzVyPUeyO{45QSCwTR?=	M1XNXHNCVkeHUh?=
P30-OHK	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTd\|MD63NUBvVQ>?	NHO5ZZlUSU6JRWK=
OMC-1	NX;lR4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlH1TWM2OD15NUGuNFkhdk1?	NYG5UXlKW0GQR1XS
LoVo	NVjLZYtJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7EXVVOUUN3ME23O\|cvQSCwTR?=	NIPEXJNUSU6JRWK=
LNCaP-Clone-FGC	NUTZVlI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGmxXVFKSzVyPUe5Ok4{PCCwTR?=	MlXwV2FPT0WU
L-363	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPueHBKSzVyPUe5PE41OiCwTR?=	MUXTRW5ITVJ?
ES8	M2e2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvpWVM2UUN3ME24NVAvPTJibl2=	M2j3WXNCVkeHUh?=
697	NGnlU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jvbmlEPTB;OEOxMlU2KG6P	NUDpeYFHW0GQR1XS
HSC-3	NEDZOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljWTWM2OD16M{muOVQhdk1?	NIXFXodUSU6JRWK=
H4	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LzWWlEPTB;OEWwMlg2KG6P	MmH2V2FPT0WU
QIMR-WIL	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTh4NT6yJI5O	MUTTRW5ITVJ?
OAW-42	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\ZR3JJUUN3ME24O\|IvOTlibl2=	NEDFc2hUSU6JRWK=
MCF7	M2TpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofiTWM2OD16OUiuOVkhdk1?	NXT3eFlJW0GQR1XS
SCC-25	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEj2T4RKSzVyPUmxOE4yQSCwTR?=	NEXLXmVUSU6JRWK=
NCI-H1563	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTlzNT65PUBvVQ>?	NXHRXo1xW0GQR1XS
OVCAR-5	NU\0XohQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DRW2lEPTB;OUSwMlE4KG6P	MnLFV2FPT0WU
HDLM-2	M13VPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHiweJhKSzVyPUm0PU4zKG6P	NFXMPYlUSU6JRWK=
NB5	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPIUnRKSzVyPUm1Ok43KG6P	MXfTRW5ITVJ?
NCI-H292	M1TBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTl5ND6zNkBvVQ>?	NW[zRm9wW0GQR1XS
A101D	NVXpNVJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTl7MD6xPUBvVQ>?	M4GyOHNCVkeHUh?=
NCI-H1648	NXTaOJloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTl7OD61NUBvVQ>?	NIjXSpRUSU6JRWK=
EKVX	NFjRU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nVU2lEPTB;MT6wNVI6KM7:TR?=	MWXTRW5ITVJ?
SW1710	NXvKV5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\xRZZKSzVyPUGuNFQzOzNizszN	MV\TRW5ITVJ?
WM-115	NW\sXYdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfKdpFKSzVyPUGuNFY3PTZizszN	M1vCSXNCVkeHUh?=
CAL-54	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfIUWdKSzVyPUGuNFcxQDFizszN	NETRc2dUSU6JRWK=
TGBC24TKB	NUm1UWFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrSTWM2OD1zLkC4NFQ2KM7:TR?=	MUHTRW5ITVJ?
NCI-H520	NXLKeJR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zKWmlEPTB;MT6wPFk3PyEQvF2=	M1HFWnNCVkeHUh?=
D-423MG	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTFwMEm5OlIh\|ryP	MoDoV2FPT0WU
BFTC-905	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LzS2lEPTB;MT6xN\|Q1QSEQvF2=	NWTHUGk{W0GQR1XS
HT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXX6Z5hUUUN3ME2xMlE{PDd6IN88US=>	NGrldohUSU6JRWK=
CTB-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M172bmlEPTB;MT6xOFI6OyEQvF2=	MW\TRW5ITVJ?
Hs-578-T	NUDZfIVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoGxTWM2OD1zLkG5OVY2KM7:TR?=	MnHWV2FPT0WU
HuH-7	M2LwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTFwMkC5OFkh\|ryP	MkD2V2FPT0WU
LB996-RCC	NGH3ZnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTFwMkKxO\|ch\|ryP	MoPpV2FPT0WU
KYSE-270	Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjRTWM2OD1zLkK5O\|M1KM7:TR?=	NX7zSZE6W0GQR1XS
A4-Fuk	NYTWUY54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vkcmlEPTB;MT6yPVk6OyEQvF2=	NV75UoI6W0GQR1XS
A498	M163S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTFwM{C0O\|Qh\|ryP	M2WwOHNCVkeHUh?=
SK-MEL-1	MoXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLyT2hKSzVyPUGuN\|A3PzlizszN	NXXGbFBVW0GQR1XS
AU565	NWHZc3plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3he3c5UUN3ME2xMlMyQDZ\|IN88US=>	MUXTRW5ITVJ?
Saos-2	NUi4Z2dNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTVWotKSzVyPUGuN\|MzODVizszN	NX;UcGhXW0GQR1XS
A549	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTFwM{m5O{DPxE1?	NGHuPZdUSU6JRWK=
BFTC-909	NYnlPYtST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\aTWM2OD1zLkSzN\|A2KM7:TR?=	NHvjTGpUSU6JRWK=
MDA-MB-415	M1zoe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XLZmlEPTB;MT60PFY6OiEQvF2=	NFK3PJRUSU6JRWK=
639-V	NXi1boNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoS5TWM2OD1zLkWwNlQ2KM7:TR?=	MYXTRW5ITVJ?
A704	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwNUC3PFUh\|ryP	M{fSe3NCVkeHUh?=
PANC-03-27	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjYcWdzUUN3ME2xMlUyPDB6IN88US=>	NWHwcIRQW0GQR1XS
SK-MEL-28	M2rPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTFwNU[wPFUh\|ryP	NHu1UGNUSU6JRWK=
Ramos-2G6-4C10	NVfJWI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFwNkC3OFYh\|ryP	MYTTRW5ITVJ?
HuP-T4	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFwNkC3O\|gh\|ryP	NFrjUZFUSU6JRWK=
VA-ES-BJ	NHrjU\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPVU5dkUUN3ME2xMlYyOjdizszN	MlLjV2FPT0WU
EFM-19	NVKxTm5XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmDyTWM2OD1zLk[xPFEh\|ryP	M3Lrb3NCVkeHUh?=
G-401	M1;WNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HneWlEPTB;MT62NlE3PCEQvF2=	MYjTRW5ITVJ?
D-566MG	NWfodlVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{i3PWlEPTB;MT62NlU{KM7:TR?=	MX\TRW5ITVJ?
JVM-3	Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwNkS4O\|Uh\|ryP	NWjTfFZZW0GQR1XS
TK10	NWD2dHZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTFwNkewPFMh\|ryP	M2\kdnNCVkeHUh?=
BT-20	M{TzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fyUWlEPTB;MT62PFkxOiEQvF2=	MVPTRW5ITVJ?
EGI-1	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4K5VGlEPTB;MT64OFcxOSEQvF2=	M1\IVHNCVkeHUh?=
EW-16	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zVPWlEPTB;MT64OVE5OiEQvF2=	NXTJcYxLW0GQR1XS
NCI-H2228	NFfsbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1KwcGlEPTB;MT64OVIxOyEQvF2=	MVLTRW5ITVJ?
BB49-HNC	MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;pUGlEPTB;MT64PFY6OiEQvF2=	M{T2VXNCVkeHUh?=
G-402	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwOEm3PVch\|ryP	NHrCNJpUSU6JRWK=
NCI-H526	NEi3Xo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnnTWM2OD1zLkmxN\|kh\|ryP	NGPvZVZUSU6JRWK=
ME-180	NFW4[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7wTWM2OD1zLkmzOFc4KM7:TR?=	M3PQ[HNCVkeHUh?=
PFSK-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrrTXBKSzVyPUGuPVQ1PThizszN	NWDpb2VoW0GQR1XS
TYK-nu	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTFwOUW4NlMh\|ryP	M3P2Z3NCVkeHUh?=
HOS	MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwOUe5OFgh\|ryP	MknwV2FPT0WU
T98G	NGK0epBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HSc2lEPTB;MT65PVAxPiEQvF2=	MV7TRW5ITVJ?
SK-MES-1	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTtNYx5UUN3ME2yMlAyOzN{IN88US=>	MW\TRW5ITVJ?
SNB75	M37RVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3z2UGlEPTB;Mj6wNVU1OSEQvF2=	NV:1bZFtW0GQR1XS
LAMA-84	NHHlS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;He41JUUN3ME2yMlAzPjh7IN88US=>	NYPKSpRoW0GQR1XS
CAL-39	NH:1OIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXIUZpKSzVyPUKuNFMzQCEQvF2=	MkKxV2FPT0WU
LOXIMVI	NFfvVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDhPY1YUUN3ME2yMlA1ODh2IN88US=>	M4fJUXNCVkeHUh?=
NH-12	NYGxZ\|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYftV\|liUUN3ME2yMlA2PDJ2IN88US=>	M3;Xb3NCVkeHUh?=
NCI-H1048	MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HtT2lEPTB;Mj6xNFUzKM7:TR?=	NFfhSHlUSU6JRWK=
KS-1	M3PnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1n5bmlEPTB;Mj6xNVAxOSEQvF2=	MYrTRW5ITVJ?
NCI-N87	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXvcIdKSzVyPUKuNVM{QDRizszN	NUfLOGpQW0GQR1XS
CHP-212	NFjOPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTJwMUi0OFIh\|ryP	M2j3OHNCVkeHUh?=
HCC1419	NVHlSm1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPvTWM2OD1{LkKxNVE2KM7:TR?=	MoPsV2FPT0WU
ES1	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HpSWlEPTB;Mj6yNVMzPiEQvF2=	MlPzV2FPT0WU
NCI-H2030	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XsT2lEPTB;Mj6yOFEzOyEQvF2=	NXv6RWR2W0GQR1XS
EW-22	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\tNWlKSzVyPUKuNlUxPjdizszN	MVrTRW5ITVJ?
A431	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{e3WWlEPTB;Mj6yO\|M2PCEQvF2=	MX7TRW5ITVJ?
SF126	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PKbmlEPTB;Mj6zNFYzPSEQvF2=	NY[yW\|d[W0GQR1XS
SF295	M32yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGW3N5ZKSzVyPUKuN\|E2OjRizszN	NWTLUJpFW0GQR1XS
D-502MG	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPkb25KSzVyPUKuN\|I1PjFizszN	MX\TRW5ITVJ?
HCC2157	NU\aV2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;5[2lEPTB;Mj6zNlkzPyEQvF2=	NHT3eGJUSU6JRWK=
D-283MED	NGCxXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnzPYdvUUN3ME2yMlM2QTJ4IN88US=>	MXTTRW5ITVJ?
SNU-423	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fvZWlEPTB;Mj60NFE4OSEQvF2=	M2rRcXNCVkeHUh?=
SK-LU-1	NUm2OJZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknETWM2OD1{LkS0OVg3KM7:TR?=	NWnxSYNEW0GQR1XS
22RV1	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvDeW1KSzVyPUKuOFU3OTdizszN	M4LKWnNCVkeHUh?=
SW1088	NXm2fmNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPtTWM2OD1{LkS5NlE{KM7:TR?=	MnXSV2FPT0WU
HT-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7V[XVrUUN3ME2yMlQ6OjV7IN88US=>	MmC4V2FPT0WU
NCI-H1666	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzYUo11UUN3ME2yMlUyOTB2IN88US=>	MonlV2FPT0WU
EM-2	NUfsd444T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInIOnRKSzVyPUKuOVEyPjlizszN	NFm1fXZUSU6JRWK=
SNU-449	NVTH[VRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H3V2lEPTB;Mj61O\|AyPCEQvF2=	NYLncW9rW0GQR1XS
786-0	MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJwNUmyN\|gh\|ryP	NYnzN2oyW0GQR1XS
SKG-IIIa	NV3DSFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJwNkW5N\|kh\|ryP	MXXTRW5ITVJ?
MEL-HO	M2\FUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TYN2lEPTB;Mj62O\|Y{PCEQvF2=	NHz5bG9USU6JRWK=
LCLC-97TM1	NHXtcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPrVIhKSzVyPUKuOlkzPjdizszN	MmjmV2FPT0WU
MKN7	NV23ZnBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIr2bZBKSzVyPUKuO\|A4PTRizszN	M1fYe3NCVkeHUh?=
5637	NV3hSJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTJwN{GwN\|Uh\|ryP	NVPXfIlwW0GQR1XS
HOP-92	M1nwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[xb4RKSzVyPUKuO\|Q4OTdizszN	MnvUV2FPT0WU
MDA-MB-157	NIrqc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\6XmlEPTB;Mj64NlAzOyEQvF2=	MmDuV2FPT0WU
NB12	M361SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXZSZl2UUN3ME2yMlg1QTF2IN88US=>	MU\TRW5ITVJ?
DMS-273	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfETWM2OD1{Lki2OFch\|ryP	NFPGOWtUSU6JRWK=
HCC70	NHnnb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfZS5hKSzVyPUKuPFY2QDlizszN	NV3JR3RWW0GQR1XS
YKG-1	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPEdW1QUUN3ME2zMlA{Pzh5IN88US=>	NH\obZhUSU6JRWK=
NCI-H28	M4r3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nzVWlEPTB;Mz6wOVI6OSEQvF2=	M1TJbnNCVkeHUh?=
HN	NFrEe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDvZmFKSzVyPUOuNFY3OzZizszN	NHfab\|hUSU6JRWK=
HT-1080	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTNwMEi2NFYh\|ryP	MVXTRW5ITVJ?
HPAF-II	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLmVVhKSzVyPUOuNVAxPjhizszN	MnHQV2FPT0WU
U-2-OS	NH\MTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTNwMUO3PFIh\|ryP	M1P2UHNCVkeHUh?=
SNU-387	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfYbXJsUUN3ME2zMlE3OzZ2IN88US=>	NWLi[2ZRW0GQR1XS
Becker	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{W4[mlEPTB;Mz6xOlgxQCEQvF2=	NWHxblQxW0GQR1XS
BHY	M1u2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[yTWM2OD1\|LkK1OVcyKM7:TR?=	MV3TRW5ITVJ?
HTC-C3	M{nvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3rdXJKSzVyPUOuNlk{PTJizszN	MX\TRW5ITVJ?
M14	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjGTGlOUUN3ME2zMlMxPjZ\|IN88US=>	MlLsV2FPT0WU
COR-L23	NFm1NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vRPGlEPTB;Mz6zO\|I4QSEQvF2=	MUHTRW5ITVJ?
C32	M1Pi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TLNmlEPTB;Mz60NVUxQCEQvF2=	NFHWO3BUSU6JRWK=
Mewo	NYDyd2tPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnixTWM2OD1\|LkSyNVgzKM7:TR?=	NIPLWItUSU6JRWK=
TE-8	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYX3UWY4UUN3ME2zMlQ5OjV7IN88US=>	MUfTRW5ITVJ?
RPMI-2650	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTNwNkC2N\|ch\|ryP	M{KzT3NCVkeHUh?=
AGS	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTNwNkK0OlQh\|ryP	NH:3[npUSU6JRWK=
MZ2-MEL	NE\XT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\sUnpMUUN3ME2zMlY3OTN6IN88US=>	NV3GXWEzW0GQR1XS
Calu-3	M2H3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHRT2tKSzVyPUOuO\|EzQDdizszN	NF\ZU5BUSU6JRWK=
SJSA-1	MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mln3TWM2OD1\|LkexN\|E2KM7:TR?=	NXvZd3g3W0GQR1XS
SW962	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnFWHNSUUN3ME2zMlczPjN4IN88US=>	MomyV2FPT0WU
PC-14	NVLxXoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvBTWM2OD1\|LkezNlIzKM7:TR?=	MnXZV2FPT0WU
SW1573	NXywc4N5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{X4VmlEPTB;Mz63OVM1QCEQvF2=	MmTmV2FPT0WU
769-P	NGHwd4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTnTWM2OD1\|LkiyO\|Q{KM7:TR?=	M3zMcHNCVkeHUh?=
KNS-62	NVm4SIMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFW2V4lKSzVyPUOuPVI{OzhizszN	MXLTRW5ITVJ?
NCI-H747	NHPJN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjyc3ZKSzVyPUSuNFU3OzhizszN	NG\IO4pUSU6JRWK=
LN-405	NV:0PZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rzU2lEPTB;ND6xOVczQCEQvF2=	MY\TRW5ITVJ?
OVCAR-8	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTRwMkK1OFMh\|ryP	NXSxNXpEW0GQR1XS
DMS-114	NGrW[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;JT2NXUUN3ME20MlI{QDlzIN88US=>	MX3TRW5ITVJ?
NCI-H2126	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTRwMkS1OVgh\|ryP	NIPufoFUSU6JRWK=
TCCSUP	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPze2drUUN3ME20MlI1Pzh6IN88US=>	MnH4V2FPT0WU
SK-N-FI	NUiwUZFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;4XmlEPTB;ND6yOVM{OiEQvF2=	MYTTRW5ITVJ?
HCE-4	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LibmlEPTB;ND6yO\|E6PyEQvF2=	NF:4[plUSU6JRWK=
DK-MG	M4WzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\UTmlEPTB;ND6zNFM6KM7:TR?=	MWrTRW5ITVJ?
RO82-W-1	NYrKdY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTRwM{K1PFQh\|ryP	M37wS3NCVkeHUh?=
A2780	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoO5TWM2OD12LkO2OlgzKM7:TR?=	NX3iOGF5W0GQR1XS
ETK-1	NGW5SHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTRwM{ewOVIh\|ryP	NFPlWI1USU6JRWK=
FADU	NUHQUGdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrSWJpKSzVyPUSuN\|c1PjdizszN	MYjTRW5ITVJ?
CAL-12T	NWjtOpBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDaTWM2OD12LkSxOFE{KM7:TR?=	M{DkPXNCVkeHUh?=
647-V	NX3wNHNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLsTIlKSzVyPUSuOFQxOjJizszN	MXfTRW5ITVJ?
TGBC1TKB	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTRwNEWxNVMh\|ryP	NXrNcGNrW0GQR1XS
LU-99A	NEm4fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHuTWM2OD12LkS2NFYh\|ryP	NHHyWFZUSU6JRWK=
CAL-33	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3Ib2VKSzVyPUSuOVI1PTZizszN	NX\RWmNSW0GQR1XS
LU-134-A	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4q4WGlEPTB;ND61Nlc1PSEQvF2=	MoLBV2FPT0WU
NCI-H1355	NF\vR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vGe2lEPTB;ND61OVE1PiEQvF2=	Ml;oV2FPT0WU
RPMI-7951	NFfKPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3S4PWlEPTB;ND61O\|AxOiEQvF2=	MWrTRW5ITVJ?
TE-1	Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny2TWM2OD12Lk[2NVQ{KM7:TR?=	NXv2W\|lTW0GQR1XS
OE33	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTRwN{C1NVEh\|ryP	NXLpT5lbW0GQR1XS
CAL-51	M37OS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTRwN{GwPFIh\|ryP	M3n6[nNCVkeHUh?=
SW1783	NHjFWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHTTWM2OD12Lke1N\|A5KM7:TR?=	MYHTRW5ITVJ?
BT-474	NFzqcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHUPVVKUUN3ME20Mlc3Ozh2IN88US=>	NWPhdJRIW0GQR1XS
KYSE-520	M1;JRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\JTWM2OD12Lki3N\|kzKM7:TR?=	MUDTRW5ITVJ?
8-MG-BA	NVLSenQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTRwOEi1OVch\|ryP	M4jEVXNCVkeHUh?=
IA-LM	NFO4SWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:4WYNKSzVyPUSuPVk1OzVizszN	NVvtXZhXW0GQR1XS
SW954	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTRwOUm0OFMh\|ryP	NU\we5hWW0GQR1XS
RPMI-8226	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDUSo5KSzVyPUWuNFU1PjFizszN	M{DYN3NCVkeHUh?=
MKN1	NWTsTIdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWexPVJsUUN3ME21MlA4QTJ5IN88US=>	NFTjTYRUSU6JRWK=
A375	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXlWnYxUUN3ME21MlA6OjV4IN88US=>	MV3TRW5ITVJ?
8305C	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[yZmU{UUN3ME21MlA6QDh5IN88US=>	MX\TRW5ITVJ?
CAL-62	MlnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTVwMUiyOVkh\|ryP	NGXVNlVUSU6JRWK=
NB10	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnJZZJrUUN3ME21MlIzPzR2IN88US=>	NXrSb3FmW0GQR1XS
OC-314	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDrR21KSzVyPUWuN\|c1PDRizszN	MkPIV2FPT0WU
PSN1	NYHqRWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;FVGtKSzVyPUWuN\|gzQDZizszN	MUjTRW5ITVJ?
GR-ST	NV75PG9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTVwM{izNlIh\|ryP	M{nCU3NCVkeHUh?=
P12-ICHIKAWA	M{G1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;ITWM2OD13LkSwNUDPxE1?	NFPDSmdUSU6JRWK=
NCI-H1092	M{W1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHSTWM2OD13LkSxNVQ5KM7:TR?=	MY\TRW5ITVJ?
SCC-4	M1[3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTSTWM2OD13LkSxN\|U2KM7:TR?=	NHS2UGRUSU6JRWK=
TE-6	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkezTWM2OD13LkSxPFE3KM7:TR?=	MUDTRW5ITVJ?
DOHH-2	MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTDTWM2OD13LkSyNlQ5KM7:TR?=	NEHLOHpUSU6JRWK=
SW684	NHXUNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnWN4pKSzVyPUWuOlY{QDVizszN	NITwdVJUSU6JRWK=
CP50-MEL-B	NX:4Tmh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnXTWM2OD13Lk[4Olg1KM7:TR?=	MUDTRW5ITVJ?
UM-UC-3	NEfjcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Lw[WlEPTB;NT63NlI{OSEQvF2=	NEDNWG5USU6JRWK=
LC-2-ad	NGC2W2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTVwN{iyOVEh\|ryP	M2DwRnNCVkeHUh?=
PC-3	NHr3SItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrRfm03UUN3ME21MlkyPjF3IN88US=>	NIjudZZUSU6JRWK=
CAN	NFnjZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHSTWM2OD13LkmyPFIh\|ryP	NF7U[GJUSU6JRWK=
ESS-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu4U3lKSzVyPUWuPVc5PjlizszN	M13Cb3NCVkeHUh?=
ATN-1	NXfubpk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX73cnpjUUN3ME22MlA2PTZ6IN88US=>	MW\TRW5ITVJ?
BxPC-3	M3fhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:zfGlLUUN3ME22MlA5OjF7IN88US=>	NULseZdyW0GQR1XS
KYSE-150	M{Kyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPnPG1KSzVyPU[uNVI1PzZizszN	M4qyN3NCVkeHUh?=
RPMI-8866	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjiTWM2OD14LkG5NVY{KM7:TR?=	NFvSVYNUSU6JRWK=
SW780	NEC3TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfYN5RMUUN3ME22MlIxPDJizszN	M1zSZnNCVkeHUh?=
A388	M{HGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXOeoh6UUN3ME22MlI{OTF3IN88US=>	NYfjPFl3W0GQR1XS
NCI-H1437	M{LB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LzRWlEPTB;Nj6yOFA4OyEQvF2=	MVjTRW5ITVJ?
NCI-H1755	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TV[GlEPTB;Nj6zOlYyOiEQvF2=	MnfsV2FPT0WU
LS-123	MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\FSnRKSzVyPU[uOFA2OjFizszN	MULTRW5ITVJ?
CaR-1	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTZwNE[zO\|Mh\|ryP	NEHpcGtUSU6JRWK=
RT-112	MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTZwNkCzN\|gh\|ryP	MYfTRW5ITVJ?
CGT	NXvzb5NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFj6Xo1KSzVyPU[uO\|M3QDFizszN	NWXYSZlnW0GQR1XS
SW626	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXOd5dpUUN3ME22Mlc{QTR4IN88US=>	M{j4ZXNCVkeHUh?=
AsPC-1	M4jzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfScIxKSzVyPU[uO\|Q2ODdizszN	MkHRV2FPT0WU
SBC-5	M3vLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTxUVFKSzVyPU[uPVczQTdizszN	NXO5WJpPW0GQR1XS
SF539	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofNTWM2OD14Lkm5N\|M{KM7:TR?=	NG\uU5BUSU6JRWK=
TI-73	NHqzenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrPUFNKSzVyPUeuNFYzQDVizszN	NHj2eZdUSU6JRWK=
MHH-ES-1	NFzaRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWG2OlZTUUN3ME23MlA4PzZ{IN88US=>	NFLyRYFUSU6JRWK=
KYSE-510	NUn1fIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPLO3p1UUN3ME23MlA5PDN{IN88US=>	MVrTRW5ITVJ?
EW-1	MnuxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnqTWM2OD15LkO2PVk3KM7:TR?=	NWrxO2lHW0GQR1XS
SK-OV-3	NHqzfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnm3TWM2OD15LkO5OFMzKM7:TR?=	NUjpNGd[W0GQR1XS
MC-IXC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HpWWlEPTB;Nz60NVk4OiEQvF2=	MYPTRW5ITVJ?
HSC-2	NV3N[ZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVi1V\|J{UUN3ME23MlQzPzB3IN88US=>	M33sT3NCVkeHUh?=
NCI-H2342	NHPnN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjGemlKSzVyPUeuOVE1QSEQvF2=	NWHzbGp5W0GQR1XS
NCI-H1792	M3XMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoXsTWM2OD15LkWxO\|EyKM7:TR?=	M1myPHNCVkeHUh?=
HT-1376	MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTdwOEe3O\|gh\|ryP	M4XKfnNCVkeHUh?=
EW-13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULud21tUUN3ME23Mlg6QTd5IN88US=>	M4W5fnNCVkeHUh?=
no-11	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHL4W3JKSzVyPUeuPVAyPzRizszN	MnPOV2FPT0WU
Daoy	M{DhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvFTWM2OD15Lkm0N\|IyKM7:TR?=	NILuNHVUSU6JRWK=
COLO-800	NWrxUWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzWflJzUUN3ME24MlA1OTZ{IN88US=>	NVGwVFZYW0GQR1XS
GB-1	M2XCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRThwME[1OlUh\|ryP	Mo\oV2FPT0WU
SJRH30	MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDOTWM2OD16LkG1PFc5KM7:TR?=	NH64ephUSU6JRWK=
NCI-H2291	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17GcGlEPTB;OD6yPVE5PyEQvF2=	M3P3PXNCVkeHUh?=
J82	NH31NpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLlem1KSzVyPUiuNlk1QTFizszN	MkHEV2FPT0WU
NCI-H596	NFWxb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmn0TWM2OD16LkOxOFU{KM7:TR?=	M4P5d3NCVkeHUh?=
RERF-LC-MS	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRThwM{S4OVYh\|ryP	MWXTRW5ITVJ?
RH-18	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXwT5oxUUN3ME24MlM2ODR4IN88US=>	MYPTRW5ITVJ?
SW48	NYrZN4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYH2[WNVUUN3ME24MlU6PDV\|IN88US=>	M4\sc3NCVkeHUh?=
RD	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XQVWlEPTB;OD61PVM6OSEQvF2=	NWTRW3l2W0GQR1XS
MS-1	NVvBSZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfvdodKSzVyPUiuOlE{QDdizszN	M4TMT3NCVkeHUh?=
ES6	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPhc3RKSzVyPUiuO\|MyOTlizszN	MmTXV2FPT0WU
TE-12	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRThwN{e1NFUh\|ryP	M4jpcHNCVkeHUh?=
DBTRG-05MG	NVvtUXM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDO[\|c{UUN3ME24MlkyOjF5IN88US=>	MkLiV2FPT0WU
KINGS-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13XXmlEPTB;OD65Nlk{QCEQvF2=	M4Pj[3NCVkeHUh?=
HLE	MlLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHhNJZKSzVyPUiuPVM4QDVizszN	M1\LU3NCVkeHUh?=
MHH-NB-11	M2LLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFuzSXlKSzVyPUmuNFE5OzlizszN	MoHCV2FPT0WU
U-87-MG	MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTlwMkSzNlEh\|ryP	M2TW[nNCVkeHUh?=
MN-60	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jjNGlEPTB;OT6yOFU1OiEQvF2=	MknFV2FPT0WU
SAS	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTlwMkW1PFEh\|ryP	M1zYR3NCVkeHUh?=
NCI-H446	M1PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2r0dWlEPTB;OT6zOlEh\|ryP	MVnTRW5ITVJ?
C-33-A	M33hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\XTWM2OD17LkSzPVg5KM7:TR?=	NHzRcpJUSU6JRWK=
RXF393	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYC2O5IyUUN3ME25MlQ4ODB{IN88US=>	NFPpeoxUSU6JRWK=
CGTH-W-1	NUj3dHVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1y2bmlEPTB;OT60PVM5PCEQvF2=	MULTRW5ITVJ?
RCM-1	NGDWNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljZTWM2OD17Lk[zPFAyKM7:TR?=	NVrG[FJtW0GQR1XS
SN12C	M4XxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PTRmlEPTB;OT62OVM{QCEQvF2=	M4TNSnNCVkeHUh?=
KLE	MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fsdGlEPTB;OT63NFAxQSEQvF2=	MXHTRW5ITVJ?
EFO-21	M2TNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoS3TWM2OD17Lke3N\|gzKM7:TR?=	M1nWUXNCVkeHUh?=
KYSE-70	M3LGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTlwOEiwNVEh\|ryP	M4rvdHNCVkeHUh?=
D-247MG	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHTSFZKSzVyPUGwMlA2PjhizszN	NY\Re3M2W0GQR1XS
MPP-89	MnXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rQO2lEPTB;MUCuNFk1PiEQvF2=	MojtV2FPT0WU
RVH-421	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTFyLkG1NFUh\|ryP	NVS5WnVkW0GQR1XS
NCI-H460	NY\XSnJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTFyLkK4NFYh\|ryP	M4Lh[nNCVkeHUh?=
NOMO-1	NHnxRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;rWmlEPTB;MUCuN\|U{OiEQvF2=	M3nTWnNCVkeHUh?=
DEL	NFfJOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjxZXJYUUN3ME2xNE4{Pzl2IN88US=>	NEOzOZJUSU6JRWK=
HT55	NGK4NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFyLk[yNFUh\|ryP	MknwV2FPT0WU
MC116	NH\xVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkGzTWM2OD1zMD62OlU2KM7:TR?=	MoLSV2FPT0WU
BB30-HNC	M{K4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PJd2lEPTB;MUCuOlY6KM7:TR?=	M3;kVHNCVkeHUh?=
DJM-1	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmr2TWM2OD1zMD62PVQ6KM7:TR?=	MXrTRW5ITVJ?
ZR-75-30	NVvxVndsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFyLkm0OFEh\|ryP	MmrPV2FPT0WU
U-118-MG	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7GZ5dKSzVyPUGwMlk5QTZizszN	NEjoe25USU6JRWK=
MSTO-211H	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XnSmlEPTB;MUGuNFcyPiEQvF2=	MWjTRW5ITVJ?
SW837	NF32THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jiO2lEPTB;MUGuNFk1QSEQvF2=	NGXTUW9USU6JRWK=
HuCCT1	NVrYV\|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHh[XBKSzVyPUGxMlEzQDFizszN	MmfmV2FPT0WU
RCC10RGB	M4fCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnkfplsUUN3ME2xNU4yOzVizszN	NWjN[HJsW0GQR1XS
NMC-G1	M3nNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTFzLkG0PVMh\|ryP	MYfTRW5ITVJ?
NCI-H650	MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3IbGJKSzVyPUGxMlM4QTRizszN	MoX6V2FPT0WU
HEC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPyVmhKSzVyPUGxMlQ{OjhizszN	MlnpV2FPT0WU
DU-4475	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHoT2hiUUN3ME2xNU44Ozl\|IN88US=>	M2jZSnNCVkeHUh?=
DSH1	NX3jO4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFzLke2NFYh\|ryP	NWDzRoNFW0GQR1XS
HCC1569	NX;JT2h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEC1XnZKSzVyPUGxMlc3PzhizszN	NVPwN2pwW0GQR1XS
HCC1187	NE\vdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnQTWM2OD1zMT64OVg5KM7:TR?=	M1HKSnNCVkeHUh?=
EW-11	M1Pjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfMU3RKSzVyPUGxMlk1PzRizszN	NIe4ephUSU6JRWK=
LB2518-MEL	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nIOWlEPTB;MUKuNFU6KM7:TR?=	MWjTRW5ITVJ?
KALS-1	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWr6NVM6UUN3ME2xNk45PTV\|IN88US=>	M3LMbHNCVkeHUh?=
8505C	NVvsNlJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv2ZnA5UUN3ME2xNk45QDVizszN	MYrTRW5ITVJ?
SK-N-DZ	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rVTGlEPTB;MUOuNFQ2OyEQvF2=	NXG1PFBzW0GQR1XS
CHP-134	M1jsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUK2O5pXUUN3ME2xN{4yOTV6IN88US=>	MnfFV2FPT0WU
HCE-T	MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDlTWM2OD1zMz6yN\|Y1KM7:TR?=	MkTHV2FPT0WU
LB-831-BLC	NEO1NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTF\|Lk[yOFYh\|ryP	NVz3TlJIW0GQR1XS
OVCAR-4	NYTtVHA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvRd\|RKSzVyPUGzMlY2OjRizszN	NX7Bd2NZW0GQR1XS
SW756	MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYm3Ro05UUN3ME2xN{44OjR4IN88US=>	MlS5V2FPT0WU
OCUB-M	NVXNR4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTUTWM2OD1zMz64NVU3KM7:TR?=	NG\pSZhUSU6JRWK=
SW982	M3r3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPmO3hKSzVyPUGzMlgzPzZizszN	M2mwTHNCVkeHUh?=
DB	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfzc\|JtUUN3ME2xN{45Ozh2IN88US=>	NHz5Tm9USU6JRWK=
H-EMC-SS	M{\3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF\|LkmxN\|kh\|ryP	MkL6V2FPT0WU
VMRC-RCZ	M3nNU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\KTWM2OD1zND6wNFE2KM7:TR?=	NHSzT4JUSU6JRWK=
CAKI-1	NUmwXHRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rH[GlEPTB;MUSuNFE{OiEQvF2=	NEXs[JNUSU6JRWK=
GI-1	NFXOTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TsVGlEPTB;MUSuNFY2QCEQvF2=	M3rGTnNCVkeHUh?=
Ca9-22	NHjsTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTF2Lk[wOVQh\|ryP	MmmxV2FPT0WU
TE-5	Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTF2LkeyNFgh\|ryP	M13BNXNCVkeHUh?=
EFO-27	NVjpUXFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PWUmlEPTB;MUSuO\|YzOiEQvF2=	M{LGW3NCVkeHUh?=
CAL-72	NXHYPGc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTF2Lke3PFMh\|ryP	NX3BNHJLW0GQR1XS
GP5d	NGXJdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2G0d2lEPTB;MUWuNFQ4PCEQvF2=	MmjiV2FPT0WU
CAS-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfubJFKSzVyPUG1MlA3PiEQvF2=	NIrJSINUSU6JRWK=
A2058	NE\TWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfrTWM2OD1zNT61OlM5KM7:TR?=	NUSxUodLW0GQR1XS
PANC-08-13	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDFTWM2OD1zNT62PFU6KM7:TR?=	NH34U2pUSU6JRWK=
Detroit562	NXq3NIJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG[5SFBKSzVyPUG1MlkyOzlizszN	NGe1U2NUSU6JRWK=
PANC-10-05	NX3v[2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\r[49JUUN3ME2xOk4xQDJzIN88US=>	M2H2PHNCVkeHUh?=
KOSC-2	NWDacllmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;u[mlEPTB;MU[uNVEzPSEQvF2=	MlXhV2FPT0WU
GT3TKB	NXG5VJdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NInxdWRKSzVyPUG2MlE6QDFizszN	Mn7iV2FPT0WU
KM-H2	NWfWdZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3XfIFKSzVyPUG2MlM3PDZizszN	MmG5V2FPT0WU
LB771-HNC	NFjUfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rrTGlEPTB;MU[uOFQzOiEQvF2=	Mk\3V2FPT0WU
SF268	M37Od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTF4LkS1NkDPxE1?	NVniT5o3W0GQR1XS
OE19	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvDb29KSzVyPUG2MlUzPCEQvF2=	NVv1emhKW0GQR1XS
MLMA	NE\wbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojmTWM2OD1zNj61OVcyKM7:TR?=	NYrZOZJUW0GQR1XS
MDA-MB-231	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTF4LkexN\|Yh\|ryP	MVXTRW5ITVJ?
TGW	NFnkfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHBTWM2OD1zNj64NVAzKM7:TR?=	NIX2UZpUSU6JRWK=
MDA-MB-453	NXX3Z3hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTiTWM2OD1zNz6wNFA{KM7:TR?=	M1TiO3NCVkeHUh?=
SNU-C2B	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fnWmlEPTB;MUeuNFI{PyEQvF2=	M2qxVnNCVkeHUh?=
A427	NFTrSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYL4dZV1UUN3ME2xO{4zOzN2IN88US=>	NYfqUJhiW0GQR1XS
SK-MEL-2	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjPXlNWUUN3ME2xO{4{OjF\|IN88US=>	M2eycXNCVkeHUh?=
KURAMOCHI	M{jSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fURmlEPTB;MUeuN\|g6PyEQvF2=	NGrweG9USU6JRWK=
IST-MEL1	NWP2SHFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn4[Zd6UUN3ME2xO{46OTh{IN88US=>	NGD5fFhUSU6JRWK=
NCI-H1793	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF6LkG1PFEh\|ryP	M{fmZXNCVkeHUh?=
HCC1395	NH;0WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHSyN5FKSzVyPUG4MlU3OTFizszN	NXz2cFhtW0GQR1XS
NUGC-3	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vVN2lEPTB;MUiuOlU5PCEQvF2=	NF6wcpRUSU6JRWK=
BB65-RCC	NIPLXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTF6Lk[2PUDPxE1?	M2\x[3NCVkeHUh?=
RMG-I	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnS5TWM2OD1zOD63N\|gzKM7:TR?=	NXPsW3R[W0GQR1XS
LS-513	MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjKTWM2OD1zOD65NlI5KM7:TR?=	NYj1UoZWW0GQR1XS
MFM-223	NFnhSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnZTWM2OD1zOT6wO\|E3KM7:TR?=	NXfp[ZV[W0GQR1XS
NCI-H727	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XvdGlEPTB;MUmuN\|I6PSEQvF2=	M2\VSHNCVkeHUh?=
KP-4	NFHUVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTF7Lki1N\|Eh\|ryP	NGP3WldUSU6JRWK=
NB13	NHXYfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;4TWM2OD1zOT64PFM6KM7:TR?=	MmrSV2FPT0WU
UACC-893	M1zKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF7Lkm3OVch\|ryP	MYnTRW5ITVJ?
HT-1197	NV:0ZVd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn3N3lKSzVyPUKwMlI6PThizszN	NIfwdJJUSU6JRWK=
NCI-H2029	NFLDSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1n1OmlEPTB;MkCuN\|I3PiEQvF2=	NFLuRndUSU6JRWK=
GI-ME-N	NInYVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2PtPWlEPTB;MkCuN\|M4OyEQvF2=	NHHXZmVUSU6JRWK=
OVCAR-3	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjpTWM2OD1{MD61PFIzKM7:TR?=	NXOwWFFWW0GQR1XS
HD-MY-Z	NYWwVVlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfmeFFKSzVyPUKxMlM3QTZizszN	MoDoV2FPT0WU
NTERA-S-cl-D1	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUT0ZZA6UUN3ME2yNU43PzJ{IN88US=>	M322RXNCVkeHUh?=
SCH	NYHzb5NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFW3NYVKSzVyPUKyMlQ6PiEQvF2=	MYLTRW5ITVJ?
KARPAS-299	NITOUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T1VmlEPTB;MkOuN\|g5PyEQvF2=	MYrTRW5ITVJ?
NCI-H1650	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPnTWM2OD1{Mz65NlQyKM7:TR?=	NFXUVVNUSU6JRWK=
ACHN	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHCRlJDUUN3ME2yOE41PjV4IN88US=>	MXzTRW5ITVJ?
M059J	MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PmcGlEPTB;MkSuOVY{PCEQvF2=	M4PWTnNCVkeHUh?=
AM-38	NFLEVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTJ3LkS4NUDPxE1?	MmnVV2FPT0WU
KG-1	M37Scmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLjepNKSzVyPUK1MlU1QTRizszN	MWTTRW5ITVJ?
COLO-824	M3zMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn5TWM2OD1{NT61OVk6KM7:TR?=	M1HRNHNCVkeHUh?=
NCI-H1155	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTJ3LkW4OFch\|ryP	MXfTRW5ITVJ?
NCI-H441	NHvNfopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVr4R2NMUUN3ME2yOU44PDZ3IN88US=>	NFTWV2VUSU6JRWK=
J-RT3-T3-5	M130O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PjbGlEPTB;Mk[uN\|AzPyEQvF2=	M4\tPHNCVkeHUh?=
JEG-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4P1RmlEPTB;Mk[uOlgxPSEQvF2=	MlnGV2FPT0WU
RKO	M{m2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXwPHRKSzVyPUK2Mlc3OzJizszN	NYXqOmpzW0GQR1XS
CAL-85-1	NVXJV4ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnUV4lKSzVyPUK3MlIyOThizszN	Mmj5V2FPT0WU
CAL-120	NGjPeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTJ5Lk[5NVQh\|ryP	NVHEUGVnW0GQR1XS
NCI-H2452	M3fWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf4bphKSzVyPUK3Mlc4OTZizszN	NGjFdZhUSU6JRWK=
NCI-H1395	NUjrdG5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zDbmlEPTB;MkeuO\|g{OyEQvF2=	NU\1dZF4W0GQR1XS
KYSE-450	M1j0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jCNWlEPTB;MkeuPVg3OiEQvF2=	MojSV2FPT0WU
S-117	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTwTWM2OD1{OT6zPFU4KM7:TR?=	M{T3XHNCVkeHUh?=
SW13	MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTQXXF3UUN3ME2yPU45PTF7IN88US=>	M{\RNnNCVkeHUh?=
ES3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfDTVFDUUN3ME2zNE4{PzN\|IN88US=>	M37LSHNCVkeHUh?=
HCT-116	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vsWmlEPTB;M{CuOVU2PCEQvF2=	M2X1R3NCVkeHUh?=
NCI-H1693	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnn0TWM2OD1\|MD61PVQzKM7:TR?=	NUm4O4pQW0GQR1XS
VM-CUB-1	M4rTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLxSY1KSzVyPUOwMlY1OTNizszN	M1vuRnNCVkeHUh?=
NCI-H2170	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LEd2lEPTB;M{GuOVc5PCEQvF2=	MVnTRW5ITVJ?
ALL-PO	NH23[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHDWZVKSzVyPUOxMlg1OjhizszN	MVPTRW5ITVJ?
NCI-H661	M2\HXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTiTWM2OD1\|Mj6wOlI{KM7:TR?=	NWrUcodvW0GQR1XS
NCI-H2347	M2jF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LXS2lEPTB;M{KuOFg{PyEQvF2=	NWSxWnBbW0GQR1XS
FTC-133	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTN{LkewOkDPxE1?	MVjTRW5ITVJ?
COLO-829	NX7aWVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzHU2pKSzVyPUOzMlM1PjdizszN	M3TzTnNCVkeHUh?=
GOTO	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnGzTWM2OD1\|Mz61NlU5KM7:TR?=	NVG4bW54W0GQR1XS
YAPC	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fufWlEPTB;M{OuPFE2QSEQvF2=	MkOyV2FPT0WU
LCLC-103H	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2D1ZmlEPTB;M{SuNVYzPCEQvF2=	NU\4ZlNSW0GQR1XS
SiHa	M1TWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfJOFdJUUN3ME2zOE4{QDF5IN88US=>	NXPQU2pIW0GQR1XS
LK-2	NYmzPVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHYcYhKSzVyPUO0MlU4ODhizszN	NXHqbZV1W0GQR1XS
KP-N-YS	M4f4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkP2TWM2OD1\|ND63NlAzKM7:TR?=	NGLDOHVUSU6JRWK=
NCI-SNU-1	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfLcY9WUUN3ME2zOU4yPzlizszN	M{fZdnNCVkeHUh?=
KNS-81-FD	NH7uXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTN3Lk[2N{DPxE1?	MlnlV2FPT0WU
SCC-9	M1\tOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTN4LkexOFYh\|ryP	MkX5V2FPT0WU
SH-4	M{Lpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTN4LkezJO69VQ>?	Ml7NV2FPT0WU
HCC-1954	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;UTWM2OD1\|Nz6yO\|I6KM7:TR?=	MkjPV2FPT0WU
BALL-1	NWfSS4ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPSe29KSzVyPUO3MlU{OTZizszN	Mmr1V2FPT0WU
BE-13	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFHNbWpKSzVyPUO3MlcxOThizszN	NYfUcVJiW0GQR1XS
COLO-678	NYT5eXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTN5Lkm0N\|ch\|ryP	M{PZd3NCVkeHUh?=
SK-MEL-3	NGK3XnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXK4W4dMUUN3ME2zPE4zOzl5IN88US=>	NEHmdYNUSU6JRWK=
OAW-28	NXiw[YVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTN6Lk[zPUDPxE1?	MlXRV2FPT0WU
CAMA-1	M1X6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\iOotJUUN3ME2zPE46PjlzIN88US=>	MofIV2FPT0WU
C2BBe1	MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\CTWM2OD1\|OT64NVgh\|ryP	NIPEcI9USU6JRWK=
A3-KAW	Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3HS4xKSzVyPUSwMlM3PjFizszN	NH[3bWpUSU6JRWK=
SK-MEL-24	NWi4d3NKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{mzPWlEPTB;NECuOVk{OSEQvF2=	NYTDVmNHW0GQR1XS
KYSE-140	M{m3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrTeoZKSzVyPUSwMlcyPjVizszN	MWPTRW5ITVJ?
MOLT-16	NEDqeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\hTWM2OD12MT6xOVM3KM7:TR?=	NWi4RYNlW0GQR1XS
CFPAC-1	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\ybWJ{UUN3ME20Nk42OjFzIN88US=>	MoTaV2FPT0WU
NB14	M{HscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:3bGlEPTB;NEKuO\|AzPyEQvF2=	M4n1cXNCVkeHUh?=
COLO-792	Mon1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTR{Lki5OlEh\|ryP	MnXYV2FPT0WU
RH-1	MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTR\|LkS4N\|Yh\|ryP	NGPxOG9USU6JRWK=
NCI-H522	M3rsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTR2LkO1Olgh\|ryP	M3PBcHNCVkeHUh?=
Ca-Ski	NVXsWmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTR2LkixNVQh\|ryP	NVj1Tm1qW0GQR1XS
KGN	Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLufXN2UUN3ME20PE4{ODZ\|IN88US=>	NX7L[FVjW0GQR1XS
UACC-62	NFL1PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTR6LkSwO\|Ih\|ryP	NHnMZ3RUSU6JRWK=
NCI-H358	M2DQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTsTWM2OD12OT6zNFE5KM7:TR?=	NWPMe5RuW0GQR1XS
LS-411N	NVW1bmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYflZpJFUUN3ME20PU4{OTF6IN88US=>	MYfTRW5ITVJ?
IST-MES1	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXYTVk5UUN3ME20PU42PjJ3IN88US=>	MorzV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

体内研究

在微粒体中，GDC-0941仅有有限的代谢，其口服生物利用度为78%^[5]。GDC-0941 每天按 75 mg/kg剂量处理携带人U87MG 恶性胶质移植瘤的雌性NCr无胸腺小鼠，显著抑制生长，肿瘤生长抑制率为 83%。^[1]GDC-0941 每天按 150 mg/kg剂量口服处理携带HER2扩增的抗Trastuzumab的MDA-MB-361.1移植瘤的小鼠，抑制肿瘤生长，且显著延迟肿瘤衰退，与肿瘤中强诱导型凋亡相关。^[2] GDC-0941 每天按75 mg/kg剂量处理携带自发性B细胞滤泡性淋巴瘤的PTEN^+/-LKB1^+/hypo小鼠，持续2周，诱导肿瘤体积下降~40%，伴随着AKT, S6K 和SGK(血清和糖皮质激素蛋白激酶)蛋白激酶的磷酸化被切除。GDC-0941抑制肿瘤细胞增殖，诱导凋亡和抑制中心母细胞数。^[3]

激酶实验： ^[1]	- 合并闪烁接近检测: 使用p85α调节亚基，使重组人PI3Kα, PI3Kβ, 和PI3Kδ在 Sf9 杆状病毒系统中共表达，在谷胱甘肽-琼脂糖凝胶上进行亲和层析而纯化GST-融合蛋白。重组人 PI3Kγ表达作为单体 GST融合，也想上述相似方法纯化。GDC-0941 溶于DMSO，加到含200 μg硅酸钇(Ysi) 聚赖氨酸SPA 磁珠, 4 mM MgCl₂, 1 mM 二硫苏糖醇 (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, 和4% (v/v) DMSO的20 mM Tris-HCl (pH 7.5)上，总体积为 50 μL。PI3Kα (5 ng), PI3Kβ(5 ng), PI3Kδ(5 ng), 或PI3Kγ(5 ng)的重组GST-融合，加到实验混合物中，开始激酶反应。在室温下温育1小时后, 加入150 μL PBS终止反应。混合物在2000 rpm 转速下离心2分钟，然后使用Wallac Microbeta计数器读数。在 MDL Assay Explorer系统中使用S型，剂量-反应曲线，计算进行至少2次独立重复实验，取平均值，作为IC50值。
细胞实验： ^[2]	- 合并 Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, 和MKN-7 Concentrations: 溶于DMSO,终浓度为~10 μM Incubation Time: 48,和72小时 Method: 使用不同浓度 GDC-0941处理细胞48,和 72小时。通过CellTiter-Glo Luminescent细胞活性检测实验测定细胞增殖/活力。通过Western Blot分析pAKT (Ser473), cleaved caspase-3, 和cleaved PARP通过 Caspase-Glo 3/7实验和细胞死亡检测 ELISAplus 实验分别测定caspase 3/7活性, 和凋亡。 (Only for Reference)
动物实验： ^[2]	- 合并 Animal Models: 移植MDA-MB-361.1细胞的NCR裸鼠, 皮下移植BT474-M1 细胞的SCID, C.B-17/IcrHsd-Prkdc^scid 小鼠 Dosages: ~150 mg/kg/day Administration: 口服饲喂 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Pictilisib (GDC-0941) SDF

分子量	513.64
化学式	C₂₃H₂₇N₇O₃S₂
CAS号	957054-30-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	RG7321

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):

研究领域

产品类型